多重用药与抗胆碱负荷同美国老年人炎症的关联:一项人群研究
该研究基于美国国家健康与营养调查(NHANES)1999-2020年数据,纳入11,647名65岁及以上、报告使用处方药的老年人,分析多重用药和抗胆碱负荷(AB)与全身炎症的关联。结果显示,过度多重用药(hyperpolypharmacy)与CRP水平升高约40%相关,而单纯多重用药与CRP无独立关联;多种AB量表评估的高抗胆碱负荷与CRP升高约16%至44%相关。多重用药合并AB时CRP水平最高。
要点
- 过度多重用药与CRP升高约40%相关,单纯多重用药与CRP无独立关联。
- 多种抗胆碱负荷量表评估的高AB与CRP升高约16%至44%相关。
- 多重用药与AB同时存在时CRP水平最高,提示需关注抗胆碱特性。
核心结论
- 在美国老年人中,抗胆碱负荷与全身炎症升高持续相关,尤其在合并多重用药时更为明显。
- 研究提示老年药物治疗中应重视药物的抗胆碱特性。
研究设计与样本
- 人群为基础的横断面研究,数据来自美国国家健康与营养调查(NHANES)1999-2020年。
- 共纳入11,647名65岁及以上、报告使用处方药的成年人,采用加权多变量线性回归分析关联。
主要发现
- 完全调整后,过度多重用药与CRP水平升高约40%相关(P < .001),单纯多重用药与CRP无独立关联(P = .113)。
- 抗胆碱认知负担量表、抗胆碱药物量表和抗胆碱风险量表评估的高AB及抗胆碱药物使用与CRP升高约16%至44%相关(均P < .050)。
- 与高敏CRP的关联主要体现在抗胆碱认知负担量表(P = .004),与纤维蛋白原的关联在抗胆碱药物量表最明显(P = .030)。
- 联合效应分析显示,无AB的多重用药与CRP无关联,多重用药与AB共存时CRP水平最高。
关键数值与推荐
- 多重用药按处方药数量定义,抗胆碱负荷采用多种已有AB量表评估。
- 全身炎症采用C反应蛋白(CRP)、高敏CRP、纤维蛋白原及6项血细胞计数复合指数评估。
临床怎么用
- 老年医学科处方审核时宜评估药物抗胆碱负荷,尤其对多重用药患者。
- 对高抗胆碱负荷的老年患者可考虑监测炎症相关指标并结合整体用药方案调整。
局限性
- 横断面设计无法推断因果关系。
- 研究仅纳入报告使用处方药的老年人,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Polypharmacy and anticholinergic burden (AB) are highly prevalent among older adults and have been linked to adverse health outcomes. However, their associations with systemic inflammation remain insufficiently characterized. DESIGN: Population-based cross-sectional study. SETTING AND PARTICIPANTS: Data were obtained from the US National Health and Nutrition Examination Survey (1999-2020). A total of 11,647 adults aged 65 years or older who reported prescription medication use were included. METHODS: Polypharmacy was defined by prescription medication count, and AB was evaluated using multiple established AB scales. Systemic inflammation was evaluated using C-reactive protein (CRP), high-sensitivity CRP, fibrinogen, and 6 composite indices derived from blood cell counts. Correlation matrices and weighted multivariable linear regression models were used to examine associations. RESULTS: After full adjustment, hyperpolypharmacy was associated with approximately 40% higher CRP levels (P < .001), whereas polypharmacy alone was not independently associated with CRP (P = .113). Higher AB assessed using the Anticholinergic Cognitive Burden Scale, Anticholinergic Drug Scale, and Anticholinergic Risk Scale, as well as anticholinergic medication use, was associated with approximately 16% to 44% higher CRP levels (all P < .050). Associations with high-sensitivity CRP were observed primarily for the Anticholinergic Cognitive Burden Scale (P = .004), whereas associations with fibrinogen were most evident for the Anticholinergic Drug Scale (P = .030). Joint-effect analyses further showed that polypharmacy without AB was not associated with CRP, whereas the co-occurrence of polypharmacy and AB was associated with the highest CRP levels. CONCLUSIONS AND IMPLICATIONS: Among US older adults, AB was consistently associated with elevated systemic inflammation, particularly in the context of polypharmacy. These findings underscore the importance of considering anticholinergic properties in geriatric pharmacotherapy.
引用
- Chen C, Yang Y, Yang G, et al. Associations of Polypharmacy and Anticholinergic Burden With Inflammation Among US Older Adults: A Population-Based Study. J Am Med Dir Assoc. 2026. PMID: 42407221. doi:10.1016/j.jamda.2026.106374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。